Evidence map›Paper›PMID 29633177›Full record

ArticleInfectious diseases and therapy2018

In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens.

Maren Eggers, Torsten Koburger-Janssen, Markus Eickmann, Juergen Zorn

7 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 170 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04341688 naunknown statusnot on this mapstarted 2021, after this paper: background citation

A Double Blind, Randomized Controlled Pilot Trial of Gargling Agents in Reducing Intraoral Viral Load Among Laboratory Confirmed COVID-19 Patients: GARGLES STUDY

TypeinterventionalSponsorAga Khan UniversityRan2021 to 2022Enrolled50ConditionsCovid-19ArmsGargle/Mouthwash
NCT04409873 phase2terminatednot on this mapstarted 2021, after this paper: background citation

Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19)

TypeinterventionalSponsorUniversity of California, San FranciscoRan2021 to 2022Enrolled54ConditionsCOVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus DiseaseArmsOral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash, Distilled water, Listerine Zero Mouthwash Product
NCT04410159 phase2completednot on this mapstarted 2020, after this paper: background citation

A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients

TypeinterventionalSponsorUniversiti Sains Islam MalaysiaRan2020 to 2020Enrolled20ConditionsCOVID-19ArmsPovidone-Iodine, Essential oils, Tap water
NCT04721457 phase4completednot on this mapstarted 2021, after this paper: background citation

Mouth Rinses Efficacy on Salivary SARS-CoV-2 Viral Load: A Randomized Clinical Trial

TypeinterventionalSponsorKing Abdulaziz UniversityRan2021 to 2021Enrolled90ConditionsSARS-CoV-2, COVID-19, Mouthwashes, Viral LoadArmsDistilled Water, 1% Povidone Iodine (PVP-I), 1.5% Hydrogen Peroxide (H2O2), 0.075% Cetylpyridinium Chloride (CPC), 0.1% Sodium Hypochlorite
NCT05375773 naunknown statusnot on this mapstarted 2022, after this paper: background citation

A Single-center, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Sino-nasal and Mouth Cavity Rinse With an Iodine-based Solution in Reducing Viral Load in Asymptomatic Coronavirus Diseases (COVID-19)

TypeinterventionalSponsorRuijin HospitalRan2022 to 2022Enrolled300Conditions2019 Novel Coronavirus InfectionArmsPVP-I Nasal Irrigation and gargling
NCT06272019 nacompletednot on this mapstarted 2023, after this paper: background citation

Alternative Application Methods of Pre-procedural Povidone Iodine Mouthrinse

TypeinterventionalSponsorChulalongkorn UniversityRan2023 to 2024Enrolled25ConditionsThe Retention of Iodine in Saliva Over the Time, The Comparison of Iodine in Saliva Between Gargle and SwabArmsIodine gargle
NCT07470242 nacompletednot on this mapstarted 2021, after this paper: background citation

Effectiveness and Safety of Povidone-Iodine Irrigation for Postoperative Management of Chronic Rhinosinusitis

TypeinterventionalSponsorPusan National University HospitalRan2021 to 2023Enrolled48ConditionsChronic RhinosinusitisArmsNormal Saline Nasal Irrigation, Acetylcysteine (Mucomyst) Nasal Irrigation, Povidone-Iodine Nasal Irrigation
3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. CSO (Canadian Society of Otolaryngology - Head & Neck Surgery) position paper on rhinologic and skull base surgery during the COVID-19 pandemic.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2020
    Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Article

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maren EggersLabor Prof. Gisela Enders MVZ GbR, Stuttgart, Germany. eggers@labor-enders.de.
Torsten Koburger-JanssenHygiene Nord GmbH, Greifswald, Germany.
Markus EickmannInstitute for Virology, Philipps University of Marburg, Marburg, Germany.
Juergen ZornMundipharma Research GmbH & Co.KG, Limburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecent virus epidemics and rising antibiotic resistance highlight the importance of hygiene measures to prevent and control outbreaks. We investigated the in vitro bactericidal and virucidal efficacy of povidone-iodine (PVP-I) 7% gargle/mouthwash at defined dilution against oral and respiratory tract pathogens.

methodsPVP-I was tested against Klebsiella pneumoniae and Streptococcus pneumoniae according to bactericidal quantitative suspension test EN13727 and against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses (SARS-CoV and MERS-CoV), rotavirus strain Wa and influenza virus A subtype H1N1 according to virucidal quantitative suspension test EN14476. PVP-I 7% gargle/mouthwash was diluted 1:30 with water to a concentration of 0.23% (the recommended concentration for "real-life" use in Japan) and tested at room temperature under clean conditions [0.3 g/l bovine serum albumin (BSA), viruses only] and dirty conditions (3.0 g/l BSA + 3.0 ml/l erythrocytes) as an interfering substance for defined contact times (minimum 15 s). Rotavirus was tested without protein load. A ≥ 5 log

resultsPVP-I gargle/mouthwash diluted 1:30 (equivalent to a concentration of 0.23% PVP-I) showed effective bactericidal activity against Klebsiella pneumoniae and Streptococcus pneumoniae and rapidly inactivated SARS-CoV, MERS-CoV, influenza virus A (H1N1) and rotavirus after 15 s of exposure.

conclusionPVP-I 7% gargle/mouthwash showed rapid bactericidal activity and virucidal efficacy in vitro at a concentration of 0.23% PVP-I and may provide a protective oropharyngeal hygiene measure for individuals at high risk of exposure to oral and respiratory pathogens.

fundingMundipharma Research GmbH & Co. KG (MRG).

Indexed as

Anti-infective agentsLocalMicrobial sensitivity testsMouthwashesPovidone-iodineRespiratory tract infections

Identifiers

PMID29633177
PMCPMC5986684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.